Condition: Metastatic Colorectal Cancer (mCRC) · Colorectal Neoplasms · Sponsor: Sergey Orlov, MD
This study will evaluate efficacy and safety of hydroxychloroquine combined with methotrexate, capecitabine and bevacizumab versus regorafenib in participants with refractory metastatic colorectal cancer with mutations in KRAS or NRAS genes. The hypotheses of this study are that a combination of hydroxychloroquine, methotrexate, capecitabine, and bevacizumab (compared to regorafenib) prolongs progression-free survival and overall survival, and also increases rates of objective responses and disease control.
This description comes directly from the study's public registry record.
Sergey V. Orlov, Professor · +79811957915 · orloff-sv@mail.ru
Aram A. Musaelyan, PhD · +79990263455 · a.musaelyan8@gmail.com
Always discuss trial participation with your own doctor first.
| First Pavlov State Medical University | Saint Petersburg, Sankt-Peterburg, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06949982